HIV Prevention Group Files Petition With U.S. Patents Office Alleging Gilead Delayed Improved HIV Drug Development To Gain Profits From Older Medicines
Washington Post: Gilead delayed safer HIV drug to extend monopoly profits, advocates allege “…An HIV-prevention group called PrEP4All Collaboration filed a petition Wednesday with the U.S. Patent and Trademark Office contending Gilead knew its new, improved drug — approved in 2015 and now part of Gilead’s combination therapies Genvoya and…